Abstract: The present invention relates to a two-photon fluorescent probe compound represented by Chemical Formula 1 below, and a method for imaging amyloid beta plaques using same, wherein the two-photon fluorescent probe compound according to the present invention maintains an excellent two-photon fluorescence cross-section while at the same time maintaining efficient BBB permeability by minimizing background fluorescence such that a high signal-to-noise ratio is exhibited, and can effectively image A? plaques since high selectivity and sensitivity to A? plaques are exhibited, and can thus be usefully used in the field of neurodegenerative disease research, including early diagnosis and treatment of Alzheimer's disease.

Abstract: Provided concerns a blood biomarker for discerning the cerebral deposition of amyloid beta, which is a causative material of Alzheimer's dementia. A marker according to the subject matter can conveniently and rapidly predictive of cerebral amyloid beta accumulation by use of a blood and can be effectively used in diagnosing relevant diseases including mild cognitive impairment at a preclinical level.

Abstract: Provided concerns a blood biomarker for discerning the cerebral deposition of amyloid beta, which is a causative material of Alzheimer's dementia. A marker according to the subject matter can conveniently and rapidly predictive of cerebral amyloid beta accumulation by use of a blood and can be effectively used in diagnosing relevant diseases including mild cognitive impairment at a preclinical level.

Abstract: Provided is a method for quantifying A? in plasma by treating the plasma with MPP and/or TCEP, and a method for diagnosing, using the quantifying method, whether or not clinical cognitive deterioration and pathological A? accumulation occur. Through cut-off values of measured values measured by the method for quantifying A? according to the present subject matter, it is possible to identify normal, MCI and AD subjects and determine whether or not accumulation of A? in the brain occurs, and it is possible to predict progression to AD.

Abstract: Provided is a method for quantifying A? in plasma by treating the plasma with MPP and/or TCEP, and a method for diagnosing, using the quantifying method, whether or not clinical cognitive deterioration and pathological A? accumulation occur. Through cut-off values of measured values measured by the method for quantifying A? according to the present subject matter, it is possible to identify normal, MCI and AD subjects and determine whether or not accumulation of A? in the brain occurs, and it is possible to predict progression to AD.

Abstract: Provided are a system and a method of screening for RAGE-amyloid beta peptide interaction inhibiting materials using a Transwell plate and a RAGE-expressing cell line.

Abstract: The present invention relates to a transformed plant cell expressing ?-amyloid gene, which is known as a causal substance of senile dementia in human, a transformed plant and a preparation method of the same, more particularly, to a transformed plant cell expressing tandem repeats of ?-amyloid gene, a transformed plant produced by tissue-culturing the above cells and a preparation method of the same. The transformed plant of the present invention expresses multiple ?-amyloid protein, so that the plant can be effectively used for the preparation of an oral vaccine composition for the prevention of senile dementia in human.

Abstract: The present invention relates to a transformed plant cell expressing ?-amyloid gene, which is known as a causal substance of senile dementia in human, a transformed plant and a preparation method of the same, more particularly, to a transformed plant cell expressing tandem repeats of ?-amyloid gene, a transformed plant produced by tissue-culturing the above cells and a preparation method of the same. The transformed plant of the present invention expresses multiple ?-amyloid protein, so that the plant can be effectively used for the preparation of an oral vaccine composition for the prevention of senile dementia in human.